Literature DB >> 24426245

Study of toxicity effect of pegylated nanoliposomal artemisinin on breast cancer cell line.

Neda Dadgar1, Seyed Ebrahim Alavi2, Maedeh Koohi Moftakhari Esfahani2, Azim Akbarzadeh3.   

Abstract

Nano carriers have greatly revolutionized the treatment of most diseases recently. One of these nano carriers, liposomes, has got particular significance. On the other hand, Artemisinin which is used as an effective anticancer drug has some side effects. To reduce such side effects, liposomes can be employed. In order to prepare pegylated nanoliposomal artemisinin, particular proportions of phosphatidylcholine, polyethylene glycol 2000 and artemisinin were combined. As a result, the mean diameter of nano liposomes is 455 nm. Besides, the encapsulation efficiency and the drug release from pegylated nanoliposomes for pegylated nanoliposomal artemisinin are respectively 91.62 ± 3.5 and 5.17 %. The results also show that IC50 of the produced formulation is less than that of the standard drug. This study reveals that the amount of artemisinin cytotoxicity compared to standard drug is increased by pegylated nanoliposomal formulation.

Entities:  

Keywords:  Artemisinin; Breast cancer; Nanoliposome; Pegylation

Year:  2013        PMID: 24426245      PMCID: PMC3783905          DOI: 10.1007/s12291-013-0306-3

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  14 in total

Review 1.  Peptide and protein PEGylation: a review of problems and solutions.

Authors:  F M Veronese
Journal:  Biomaterials       Date:  2001-03       Impact factor: 12.479

2.  [Relative expression of genes involved in artemisinin biosynthesis and artemisinin accumulation in different tissues of Artemisia annua].

Authors:  Lien Xiang; Zhenghui Yan; Guijun Wang; Wanhong Liu; Kexuan Tang; Zhihua Liao
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2012-05

Review 3.  Developments in liposomal drug delivery systems.

Authors:  N Maurer; D B Fenske; P R Cullis
Journal:  Expert Opin Biol Ther       Date:  2001-11       Impact factor: 4.388

Review 4.  Liposomes for oral administration of drugs.

Authors:  J F Woodley
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1985       Impact factor: 4.889

5.  Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat.

Authors:  Henry Lai; Narendra P Singh
Journal:  Cancer Lett       Date:  2006-01-08       Impact factor: 8.679

Review 6.  Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?

Authors:  Jianfeng Guo; Ludovic Bourre; Declan M Soden; Gerald C O'Sullivan; Caitriona O'Driscoll
Journal:  Biotechnol Adv       Date:  2011-03-22       Impact factor: 14.227

7.  Nanomaterials and nanoparticles: sources and toxicity.

Authors:  Cristina Buzea; Ivan I Pacheco; Kevin Robbie
Journal:  Biointerphases       Date:  2007-12       Impact factor: 2.456

Review 8.  The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.

Authors:  Rivka Yatuv; Micah Robinson; Inbal Dayan-Tarshish; Moshe Baru
Journal:  Int J Nanomedicine       Date:  2010-09-07

9.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Authors:  A Gabizon; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

Review 10.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

View more
  6 in total

1.  Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells.

Authors:  Yunfei Zhang; Wen Luo; Yucai Wang; Jun Chen; Yunyan Liu; Yong Zhang
Journal:  Oncol Rep       Date:  2015-04-27       Impact factor: 3.906

Review 2.  Design of Drug Delivery Systems Containing Artemisinin and Its Derivatives.

Authors:  Blessing Atim Aderibigbe
Journal:  Molecules       Date:  2017-02-20       Impact factor: 4.411

3.  Oxidation of Erythrocytes Enhance the Production of Reactive Species in the Presence of Artemisinins.

Authors:  Ioannis Tsamesidis; Pierre Pério; Antonella Pantaleo; Karine Reybier
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

Review 4.  Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery.

Authors:  Xinyu Zhou; Fengzhi Suo; Kristina Haslinger; Wim J Quax
Journal:  Pharmaceutics       Date:  2022-02-10       Impact factor: 6.321

5.  Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.

Authors:  Kanchan Kumari; Sunita Keshari; Debomita Sengupta; Surendra C Sabat; Sandip K Mishra
Journal:  BMC Cancer       Date:  2017-12-15       Impact factor: 4.430

Review 6.  Antitumor Research on Artemisinin and Its Bioactive Derivatives.

Authors:  Yunqin Zhang; Guowei Xu; Shuqun Zhang; Dong Wang; P Saravana Prabha; Zhili Zuo
Journal:  Nat Prod Bioprospect       Date:  2018-04-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.